Albany Molecular Research Profit Margin

The latest profit margin for AMRI is -8.78% as of June 2017. That compares with -7.37% in the prior-year period — down 19.1% year over year. That is below the sector sector average of 19.74%. Investors often review this figure alongside Albany Molecular Research's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMRI's profit margin moved from -7.37% to -8.78% — a 19.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Albany Molecular Research's valuation or profitability profile.

Against its sector companies, AMRI currently prints -8.78% for profit margin, while the sector average sits near 19.74%. That is roughly 144.5% below the sector mean. Large gaps often invite a closer look at Albany Molecular Research's growth, margins, and balance sheet.

Profit Margin shows how effectively Albany Molecular Research converts resources into returns. At -8.78%, AMRI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -7.37% in the prior-year period — down 19.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AMRI's profit margin (-8.78%), review year-over-year change from -7.37%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.